Search results
DynamX Performance in Complex Coronaries: OCT Study
Added:
2 weeks ago
Original Research
Added:
1 year ago
One-year outcomes from INFINITY-SWEDEHEART RCT recently presented at ESC 2024 demonstrated that DynamX Bioadaptor meets primary endpoint and significantly reduces adverse events compared to DES after six months. Dr David Erlinge, the primary investigator of INFINITY-SWEDEHEART RCT, shares a quick summary of the one-year outcomes presented at ESC 2024. He highlights how the novel design and…
View more
Added:
1 year ago
TCT Conference 2024 - Significant reduction in TLF and TVF and flattening of event curves after 6 months in favour of DynamX Bioadaptor.Dr David Erlinge (Skane University Hospital, Lund, SE) joins us onsite at TCT Conference to discuss the findings from INFINITY-SWEDEHEART (NCT04562805).INFINITY-SWEDEHEART is a prospective, multicenter, randomized registry-based clinical trial, where patients…
View more
Added:
6 months ago
TCT 2025 - Findings from INFINITY-SWEDEHEART show significant reductions in target vessel failure and treatment benefit after 6 months to two years with the DynamX bioadaptor stent.Prof David Erlinge (Skane University Hospital, SE) joins us to discuss findings from the INFINITY-SWEDEHEART trial, a prospective, multicenter, registry-based randomized clinical trial comparing long-term outcomes of…
View more
Added:
11 months ago
EuroPCR25 - Novel DynamX Bioadaptor demonstrates a sustained reduction of device-related events from six-month to three-year follow-up compared to drug-eluting stents (DES).We are joined by Dr Shigeru Saito (Shonan Kamakura General Hospital, Kamakura, JP) to discuss key findings from the BIOADAPTOR RCT trial (NCT04192747). This prospective, randomised controlled trial compared the ELX1805J …
View more
Added:
1 year ago
Step into the forefront of interventional cardiology with distinguished experts Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcenter, Erasmus MC, Rotterdam, NL) as they provide a comprehensive overview of EuroPCR 2025's most anticipated late-breaking trials.Optimize your conference preparation through this essential preview, where expert commentary outlines the clinical significance of this…
View more
Added:
11 months ago
Explore the Top Trials from EuroPCR 25 with Insights from the Thoraxcenter!Join Prof Nicolas Van Mieghem and Dr Joost Daemen from Erasmus MC, Rotterdam, for an engaging and critical analysis of the latest trials unveiled at EuroPCR.In this comprehensive EuroPCR review, interventional experts examine the most significant trials, providing valuable insights into their impact on current practices…
View more
Added:
1 year ago
ESC Congress 24 – Day 4 of the ESC Congress 2024 was filled with hot line and late-breaking data poised to influence cardiovascular practice.Interventional experts DrMirvat Alasnagand DrKhaled Al-Shaibi(King Fahd Armed Forces Hospital, SA) joined us to review and distil the key messages from the latest data presented at the last of the biggest cardiovascular event of 2024.Day 4 Highlights:00:19…
View more
Added:
1 year ago
Dive into our collection covering the hot line and late-breaking trials presented at EuroPCR 2025. Reviewing the sessions you don't want to miss, interventional experts Prof Nicolas Van MieghemandDr Joost Daemen will be leading our regular series View From the Thoraxcenter. For a deeper dive into the most anticipated trials, our Expert Interviews have you covered.
View more
Added:
8 months ago
Source:
TCT Conference 2025 Programme Guide
Late-breaking clinical trials and science sessions have been announced for Transcatheter Cardiovascular Therapeutics 2025 conference.The conference is set to take place from 25th to 28th October 2025 at the Moscone Center in San Francisco, CA.Access the full programme here.Late-Breaking Clinical Trials: Session I, in Collaboration with The LancetSunday 26th October, 11:00am – 12:28pm (PDT)One…
View more